CDKN1A and breast carcinoma: Xie et al. have shown that inhibiting the PI3K/AKT signaling pathway enhanced the transcriptional activity of FOXO4 associated with upregulation of the cyclin-dependent kinase (CDK) inhibitors p21Cip1 and p27Kip1 and reduced proliferation of breast cancer cells [28].